Literature DB >> 18948999

Novel therapeutic applications of cardiac glycosides.

Ioannis Prassas1, Eleftherios P Diamandis.   

Abstract

Cardiac glycosides are a diverse family of naturally derived compounds that bind to and inhibit Na+/K+-ATPase. Members of this family have been in clinical use for many years for the treatment of heart failure and atrial arrhythmia, and the mechanism of their positive inotropic effect is well characterized. Exciting recent findings have suggested additional signalling modes of action of Na+/K+-ATPase, implicating cardiac glycosides in the regulation of several important cellular processes and highlighting potential new therapeutic roles for these compounds in various diseases. Perhaps most notably, the increased susceptibility of cancer cells to these compounds supports their potential use as cancer therapies, and the first generation of glycoside-based anticancer drugs are currently in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18948999     DOI: 10.1038/nrd2682

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  182 in total

1.  A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment.

Authors:  Elizabeth A Platz; Srinivasan Yegnasubramanian; Jun O Liu; Curtis R Chong; Joong Sup Shim; Stacey A Kenfield; Meir J Stampfer; Walter C Willett; Edward Giovannucci; William G Nelson
Journal:  Cancer Discov       Date:  2011-06       Impact factor: 39.397

2.  A hearty solution for acute myeloid leukemia.

Authors:  Yi-ju Hung; H Eugene Liu
Journal:  Acta Pharmacol Sin       Date:  2012-01       Impact factor: 6.150

3.  Versatile pathway-centric approach based on high-throughput sequencing to anticancer drug discovery.

Authors:  Hairi Li; Hongyan Zhou; Dong Wang; Jinsong Qiu; Yu Zhou; Xiangqiang Li; Michael G Rosenfeld; Sheng Ding; Xiang-Dong Fu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-06       Impact factor: 11.205

4.  Magnesium lithospermate B extracted from Salvia miltiorrhiza elevates intracellular Ca(2+) level in SH-SY5Y cells.

Authors:  Yi-Ching Chen; Tzyy-Rong Jinn; Tse-Yu Chung; Feng-Yin Li; Ruey-Jane Fan; Jason Tc Tzen
Journal:  Acta Pharmacol Sin       Date:  2010-08       Impact factor: 6.150

5.  Modulation of Na(+)-K(+)-ATPase cell surface abundance through structural determinants on the α1-subunit.

Authors:  Sandrine V Pierre; Aude Belliard; Yoann Sottejeau
Journal:  Am J Physiol Cell Physiol       Date:  2010-11-03       Impact factor: 4.249

6.  Functional drug screening assay reveals potential glioma therapeutics.

Authors:  Christian E Badr; Thomas Wurdinger; Bakhos A Tannous
Journal:  Assay Drug Dev Technol       Date:  2010-12-27       Impact factor: 1.738

7.  Human cytomegalovirus inhibition by cardiac glycosides: evidence for involvement of the HERG gene.

Authors:  Arun Kapoor; Hongyi Cai; Michael Forman; Ran He; Meir Shamay; Ravit Arav-Boger
Journal:  Antimicrob Agents Chemother       Date:  2012-07-09       Impact factor: 5.191

8.  Cytotoxic cardiac glycosides and coumarins from Antiaris toxicaria.

Authors:  Li-Shian Shi; Sheng-Chu Kuo; Han-Dong Sun; Susan L Morris-Natschke; Kuo-Hsiung Lee; Tian-Shung Wu
Journal:  Bioorg Med Chem       Date:  2014-02-06       Impact factor: 3.641

9.  BDNF mediates neuroprotection against oxygen-glucose deprivation by the cardiac glycoside oleandrin.

Authors:  Michael J Van Kanegan; Dong Ning He; Denise E Dunn; Peiying Yang; Robert A Newman; Anne E West; Donald C Lo
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167

10.  Reevesioside F induces potent and efficient anti-proliferative and apoptotic activities through Na⁺/K⁺-ATPase α3 subunit-involved mitochondrial stress and amplification of caspase cascades.

Authors:  She-Hung Chan; Wohn-Jenn Leu; Lih-Ching Hsu; Hsun-Shuo Chang; Tsong-Long Hwang; Ih-Sheng Chen; Ching-Shih Chen; Jih-Hwa Guh
Journal:  Biochem Pharmacol       Date:  2013-10-04       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.